03/16/23 4:01 PMNasdaq : ETON earningsEton Pharmaceuticals Reports Fourth Quarter 2022 Financial ResultsEton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq:RHEA-AIneutral
03/15/23 6:50 AMNasdaq : ETON acquisitionEton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing andRHEA-AIneutral
03/07/23 4:05 PMNasdaq : ETON conferencesearningsEton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2022 financial results on Thursday, MarchRHEA-AIneutral
01/11/23 6:50 AMNasdaq : ETON Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol InjectionEton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focusedRHEA-AIvery positive
11/10/22 4:05 PMNasdaq : ETON earningsEton Pharmaceuticals Reports Third Quarter 2022 Financial ResultsQ3 2022 revenue of $3.2 million, product sales and royalty revenue up 315% from prior year and 37% from Q2 2022 Strong sales growth of ALKINDI SPRINKLE® and Carglumic Acid Third commercial product, Betaine Anhydrous, added to rare disease portfolio DEER PARK, Ill., Nov. 10, 2022RHEA-AIvery positive
11/02/22 4:05 PMNasdaq : ETON conferencesearningsEton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2022 financial results on Thursday, NovemberRHEA-AIneutral
10/18/22 6:50 AMNasdaq : ETON conferencesEton Pharmaceuticals to Present at the LD Micro Main Event XV ConferenceEton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, willRHEA-AIneutral
09/13/22 9:00 AMNasdaq : ETON acquisitionEton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral SolutionEton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced theRHEA-AIvery positive
08/30/22 4:05 PMNasdaq : ETON conferencesEton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceEton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, willRHEA-AIneutral
08/11/22 4:01 PMNasdaq : ETON earningsEton Pharmaceuticals Reports Second Quarter 2022 Financial ResultsTotal Q2 2022 revenue of $7.4 million, up 139% from prior year Recently launched ALKINDI SPRINKLE ® and Carglumic Acid continue to show robust growth Divestiture of hospital products division to focus on rare disease strategy U.S. Food and Drug Administration (FDA) Approval of Zonisade™ (zonisamideRHEA-AIneutral